2 terminated. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Terminated 2 |
| Phase 2 | 1 | Terminated 1 |
Follow Craniosynostoses: new trials by email Literature Review of Craniosynostoses trials Research Report on Craniosynostoses
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma Derazantinib, Derazantinib-paclitaxel-ramucirumab combination - Gastric Adenocarcinoma | Phase 1 / Phase 2 | Terminated | Basilea Pharmaceutica | 47 | 2020-10-06 | 2024-04-04 |
| An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies INCB062079 - Hepatocellular Carcinoma (HCC), Cholangiocarcinoma | Phase 1 | Terminated | Incyte Corporation | 25 | 2017-05-25 | 2025-10-21 |
Acrocephalosyndactylia (2) · Carcinoma, Hepatocellular (1) · Cholangiocarcinoma (1) · Esophageal Neoplasms (1) · Nasopharyngeal Neoplasms (1) · Ovarian Neoplasms (1) · Stomach Neoplasms (1)
Bone Diseases (2) · Bone Diseases, Developmental (2) · Congenital Abnormalities (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Craniofacial Abnormalities (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Dysostoses (2) · Gastrointestinal Diseases (2) · Gastrointestinal Neoplasms (2) · Limb Deformities, Congenital (2) · Musculoskeletal Abnormalities (2) · Musculoskeletal Diseases (2) · Neoplasms (2)
derazantinib (1)
Basilea Pharmaceutica (1) · Incyte Corporation (1)
Belgium (2) · United States (2) · Argentina (1) · Australia (1) · Brazil (1) · Chile (1) · France (1) · Germany (1) · Italy (1) · Poland (1) · Russia (1) · South Korea (1) · Spain (1) · Turkey (Türkiye) (1) · United Kingdom (1)
2017 (1)